Humana Inc is a healthcare plans business based in the US. Humana shares (HUM.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $433.08 – an increase of 0.06% over the previous week. Humana employs 46,000 staff and has a trailing 12-month revenue of around $74.4 billion.
Since the stock market crash in March caused by coronavirus, Humana's share price has had significant positive movement.
Its last market close was $433.08, which is 14.64% up on its pre-crash value of $369.67 and 107.96% up on the lowest point reached during the March crash when the shares fell as low as $208.25.
If you had bought $1,000 worth of Humana shares at the start of February 2020, those shares would have been worth $643.29 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,299.24.
|Latest market close||$433.08|
|52-week range||$207.141 - $474.7|
|50-day moving average||$408.0009|
|200-day moving average||$405.7157|
|Wall St. target price||$469.38|
|Dividend yield||$2.5 (0.62%)|
|Earnings per share (TTM)||$31.204|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-14)||-0.26%|
|1 month (2020-12-22)||3.99%|
|3 months (2020-10-22)||-8.44%|
|6 months (2020-07-22)||0.39%|
|1 year (2020-01-21)||10.71%|
|2 years (2019-01-18)||36.67%|
|3 years (2018-01-19)||44.63%|
|5 years (2016-01-21)||143.18%|
Valuing Humana stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Humana's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Humana's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Humana shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Humana's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5648. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Humana's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Humana's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $6 billion (£4.4 billion).
The EBITDA is a measure of a Humana's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$74.4 billion|
|Operating margin TTM||7.68%|
|Gross profit TTM||$11 billion|
|Return on assets TTM||10.55%|
|Return on equity TTM||30.35%|
|Market capitalisation||$53.6 billion|
TTM: trailing 12 months
There are currently 1.5 million Humana shares held short by investors – that's known as Humana's "short interest". This figure is 27.1% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting Humana shares can be evaluated.
Humana's "short interest ratio" (SIR) is the quantity of Humana shares currently shorted divided by the average quantity of Humana shares traded daily (recently around 833470.85714286). Humana's SIR currently stands at 1.75. In other words for every 100,000 Humana shares traded daily on the market, roughly 1750 shares are currently held short.
However Humana's short interest can also be evaluated against the total number of Humana shares, or, against the total number of tradable Humana shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Humana's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Humana shares in existence, roughly 10 shares are currently held short) or 0.011% of the tradable shares (for every 100,000 tradable Humana shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Humana.
Find out more about how you can short Humana stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Humana.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 25.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Humana's overall score of 25.71 (as at 01/01/2019) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Humana is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.6/100
Humana's environmental score of 2.6 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.54/100
Humana's social score of 18.54 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Humana is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.07/100
Humana's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Humana is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Humana scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Humana has, for the most part, managed to keep its nose clean.
|Total ESG score||25.71|
|Total ESG percentile||32.96|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Dividend payout ratio: 10.72% of net profits
Recently Humana has paid out, on average, around 10.72% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.62% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Humana shareholders could enjoy a 0.62% return on their shares, in the form of dividend payments. In Humana's case, that would currently equate to about $2.5 per share.
While Humana's payout ratio might seem low, this can signify that Humana is investing more in its future growth.
Humana's most recent dividend payout was on 29 January 2021. The latest dividend was paid out to all shareholders who bought their shares by 30 December 2020 (the "ex-dividend date").
Humana's shares were split on a 3:2 basis on 1 August 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Humana shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Humana shares which in turn could have impacted Humana's share price.
Over the last 12 months, Humana's shares have ranged in value from as little as $207.141 up to $474.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Humana's is 0.8446. This would suggest that Humana's shares are less volatile than average (for this exchange).
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2019, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. The company has a relationship with Cano Health, LLC to expand health centers in San Antonio and Las Vegas. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.